Omeros (NASDAQ: OMER) reported Q2 EPS of ($0.70), $0.01 worse than the analyst estimate of ($0.69).

“During the last quarter, we made significant strides across multiple fronts,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “For OMS721, our MASP-2 inhibitor, Phase 3 clinical trials are advancing in both IgA nephropathy and aHUS, and our stem-cell TMA program is moving toward regulatory filings for marketing approval in both the U.S. and Europe. Our PDE7 inhibitor OMS527 is demonstrating good drug behavior in its Phase 1 clinical trial. We are also excited about our MASP-3 inhibitor OMS906, our MASP-2 small molecules for oral administration and our multiple GPCR cancer therapeutic programs, all of which look promising and are slated to begin entering the clinic as early as late 2019. And to help fund our pipeline’s continuing progress, OMIDRIA is rapidly approaching its return to pass-through status on October 1. All of the pieces appear to be coming together, and we look forward to realizing the near- and long-term prospects for Omeros.”

For earnings history and earnings-related data on Omeros (OMER) click here.